This algorithm is broadly aligned with contemporary GIST management: upfront histologic diagnosis, mandatory KIT/PDGFRA molecular testing to guide systemic therapy, risk-adapted use of adjuvant imatin...

This algorithm is broadly aligned with contemporary adult non-APL AML practice: urgent exclusion of APL and stabilization, early comprehensive cytogenetic/molecular profiling, fitness-based selection ...

Molecular testing for pancreatic cancer at first visit and within the first 2-4 weeks.

Lung cancer management based on TNM staging, where early-stage (I–II) disease is primarily treated with surgical resection (with possible adjuvant therapy), while more advanced stages (III–IV) incorpo...

The metastatic portion is broadly aligned with current standards: comprehensive RET fusion testing at diagnosis and first-line selective RET inhibition (selpercatinib or pralsetinib) is guideline-conc...

Selection and follow-up for men with low-risk and select favorable intermediate-risk prostate cancer. Tyler Seibert, MD, PhD, Genitourinary Section Chief at UC San Diego Radiation Oncology outlines cr...

Stage-based management of thymic tumors, emphasizing complete surgical resection (via VATS/RATS or open thymectomy) for early stages, with increasing need for en bloc resection of involved structures ...

Intermediate-Risk Non–Muscle-Invasive Bladder Cancer (IR NMIBC) Risk Stratification Model by the International Bladder Cancer Group (IBCG).

Treatment algorithm for newly diagnosed myeloma patients.  Dr. Rajkumar is a contributing editor to the International Myeloma Foundation (https://www.myeloma.org/frontline-treatment-options).Watch Dr....

Treatment algorithm for Gastric, Gastroesophageal Junction (GEJ) and Esophageal Adenocarcinoma by Yelena Y. Janjigian, MD, FASCO, Chief, Gastrointestinal Oncology Service at Memorial Sloan Kettering C...

The algorithm is broadly aligned with contemporary management of primary malignant bone sarcomas: referral to a sarcoma center, histology-driven pathways, multimodality therapy for osteosarcoma and Ew...

Molecular testing for pancreatic cancer at first visit and within the first 2-4 weeks.

Dr. Rajkumar's video walk through. Treatment algorithm for smoldering myeloma. Incorporates the 2025 Daratumumab FDA approval for high risk smoldering myeloma. Active drugs in multiple myeloma referen...

This algorithm is broadly aligned with contemporary stage I testicular GCT management: confirm true clinical stage I with appropriate post-orchiectomy marker kinetics and imaging, then select surveill...

The algorithm is broadly aligned with current management of stage I–IIIB NSCLC: guideline-concordant diagnostic workup, surgery or SBRT for early-stage disease, biomarker-driven adjuvant targeted ther...

The algorithm is broadly aligned with contemporary management of platinum-sensitive recurrent epithelial ovarian cancer: use of platinum-based combinations, consideration of secondary cytoreductive su...

This belzutifan-focused pathway is broadly aligned with current evidence and labeling for advanced/metastatic ccRCC after prior PD-(L)1 inhibitor and VEGF-targeted therapy, centering on LITESPARK-005 ...

The algorithm is broadly aligned with contemporary mCRPC management: maintain ADT, perform HRR (germline/somatic) testing early, and consider PARP inhibitor combinations for HRR-altered disease. Place...

The algorithm is broadly aligned with contemporary TNBC practice: neoadjuvant pembrolizumab plus chemotherapy for high-risk early TNBC; adjuvant escalation strategies for residual disease including ca...

The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...

Treatment algorithm for newly diagnosed myeloma patients.  Dr. Rajkumar is a contributing editor to the International Myeloma Foundation (https://www.myeloma.org/frontline-treatment-options).

The algorithm is broadly aligned with current mCSPC practice for diagnosis, early treatment intensification with AR pathway inhibitors, and routine consideration of germline/somatic testing. However, ...

This algorithm is broadly aligned with contemporary stage I testicular GCT management: confirm true clinical stage I with appropriate post-orchiectomy marker kinetics and imaging, then select surveill...

This algorithm is broadly aligned with contemporary adult non-APL AML practice: urgent exclusion of APL and stabilization, early comprehensive cytogenetic/molecular profiling, fitness-based selection ...

The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...

The algorithm is broadly aligned with contemporary management of metastatic PPGL by emphasizing symptom stabilization, careful selection between observation vs treatment, and use of functional imaging...

The algorithm is broadly aligned with current first-line management of advanced/metastatic squamous NSCLC: universal biomarker testing, PD-L1–informed selection, and chemoimmunotherapy as the dominant...

Treatment algorithm for newly diagnosed myeloma patients.  Dr. Rajkumar is a contributing editor to the International Myeloma Foundation (https://www.myeloma.org/frontline-treatment-options).

The algorithm is partially aligned with current metastatic squamous NSCLC practice in its emphasis on broad molecular testing and guideline-directed targeted therapy when actionable drivers are presen...

The algorithm is broadly aligned with current practice for previously treated metastatic PDAC in emphasizing performance status assessment, clinical trial enrollment, molecular profiling, and use of e...

This algorithm (1L Metastatic Urothelial Carcinoma: EV/Pembro vs Platinum) should answer one practical question: In a patient with previously untreated unresectable or metastatic urothelial carcinoma,...

Intermediate-Risk Non–Muscle-Invasive Bladder Cancer (IR NMIBC) Risk Stratification Model by the International Bladder Cancer Group (IBCG).

Post ASCO, ESMO and SABCS 2025 TNBC algorithm. Radiation is indicated for some with early stage disease. Add Zometa for postmenopausal patients, q6 months for 2-3 years (Early stage).*Keynote522 studi...

The metastatic portion is broadly aligned with current standards: comprehensive RET fusion testing at diagnosis and first-line selective RET inhibition (selpercatinib or pralsetinib) is guideline-conc...

How Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages abdominal pain and cramping after radiation therapy (RT). Originally posted on YouTube 'Man...